| Not Yet Recruiting | Endogenous Energy Production in Critically Ill Patients NCT07059988 | Karolinska University Hospital | N/A |
| Not Yet Recruiting | Potato Diet Intervention Study in a College Population NCT06686199 | Yu Zhang | N/A |
| Unknown | Study on the Regulatory Effects of Personalized Innovative Youtiao Intervention on Nutritional Health NCT06422429 | Yu Zhang | Phase 2 |
| Completed | NUtrition and ORal Health in Orthopaedic Surgery NCT06327854 | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio | — |
| Completed | METabolism After Orthopedic Surgery NCT05864833 | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio | — |
| Active Not Recruiting | Energy Metabolism Profiles Over Weight-loss and Eating Responses NCT05785221 | Chinese Academy of Sciences | N/A |
| Unknown | The Effect of Vegetarian Diet on Patients With Metabolic Associated Fatty Liver Disease NCT05443581 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | N/A |
| Completed | A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overwei NCT05024032 | Eli Lilly and Company | Phase 3 |
| Completed | Validity and Reliability of Commercially Available Metabolic Carts NCT04995211 | Pennington Biomedical Research Center | — |
| Completed | The Effect of High vs. Moderate Protein Consumption on Human Health NCT04156165 | University of Copenhagen | N/A |
| Completed | Markers of Carnitine Acetyltransferase (CrAT) Protein Activity and Carnitine Availability NCT03697928 | Maastricht University | — |
| Terminated | Prospective Evaluation of the Incidence of PICS NCT03584399 | Indiana University | — |
| Unknown | Amino Acid Metabolism in Fed Surgical Critically Ill Patients NCT03451968 | Rabin Medical Center | N/A |
| Completed | Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity NCT03661879 | Novo Nordisk A/S | Phase 1 |
| Completed | Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity NCT03548987 | Novo Nordisk A/S | Phase 3 |
| Completed | STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity NCT03548935 | Novo Nordisk A/S | Phase 3 |
| Completed | A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight o NCT03479892 | Novo Nordisk A/S | Phase 1 |
| Completed | Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or NCT03308721 | Novo Nordisk A/S | Phase 1 |
| Completed | Awareness, Care and Treatment in Obesity Management NCT03235102 | Novo Nordisk A/S | — |
| Completed | Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity NCT03095807 | Novo Nordisk A/S | Phase 1 |
| Completed | Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Tr NCT02963922 | Novo Nordisk A/S | Phase 3 |
| Completed | Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-spec NCT02963935 | Novo Nordisk A/S | Phase 3 |
| Completed | Tight Caloric Control in the Cachectic Oncologic Patient (TiCaCONCO or CoCooN) NCT03058107 | Universitair Ziekenhuis Brussel | N/A |
| Completed | First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subject NCT03015207 | Novo Nordisk A/S | Phase 1 |
| Completed | Human Metabolic Dynamics at Rest and During Aerobic Exercise Under Normobaric Normoxic and Moderate Hypoxic Co NCT03121885 | Benjamin Gollasch | N/A |
| Completed | In-market Utilisation of Liraglutide Used for Weight Management in Europe NCT02967757 | Novo Nordisk A/S | — |
| Completed | Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-083 NCT02958085 | Novo Nordisk A/S | Phase 1 |
| Completed | A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1 NCT02941042 | Novo Nordisk A/S | Phase 1 |
| Completed | Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity NCT02918279 | Novo Nordisk A/S | Phase 3 |
| Completed | Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liragluti NCT02870231 | Novo Nordisk A/S | Phase 1 |
| Completed | A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Su NCT02835235 | Novo Nordisk A/S | Phase 1 |
| Completed | A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects. NCT02717858 | Novo Nordisk A/S | Phase 1 |
| Completed | A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children NCT02696148 | Novo Nordisk A/S | Phase 1 |
| Unknown | Improving Glucose and Lipid Metabolism Through Caloric Restriction Using Diet or Surgery (CRUDOS) NCT02988011 | Uppsala University | N/A |
| Completed | Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome NCT02527200 | Novo Nordisk A/S | Phase 3 |
| Completed | Awareness, Care & Treatment in Obesity Management (ACTION) Study NCT03223493 | Novo Nordisk A/S | — |
| Completed | A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple NCT02568306 | Novo Nordisk A/S | Phase 1 |
| Completed | Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus NCT02453711 | Novo Nordisk A/S | Phase 2 |
| Completed | Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, O NCT02300844 | Novo Nordisk A/S | Phase 1 |
| Completed | Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combinatio NCT02235961 | Novo Nordisk A/S | Phase 1 |
| Completed | Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pe NCT02207348 | Novo Nordisk A/S | Phase 1 |
| Completed | Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and NCT02079870 | Novo Nordisk A/S | Phase 1 |
| Completed | A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Li NCT01789086 | Novo Nordisk A/S | Phase 1 |
| Completed | Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoe NCT01557166 | Novo Nordisk A/S | Phase 3 |
| Completed | Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes NCT01272232 | Novo Nordisk A/S | Phase 3 |
| Completed | Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities NCT01272219 | Novo Nordisk A/S | Phase 3 |
| Recruiting | The Biological Rhythm of Human Metabolite NCT03669809 | Shandong Provincial Hospital | — |
| Terminated | A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers NCT01044108 | Novo Nordisk A/S | Phase 1 |
| Completed | A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers NCT00978393 | Novo Nordisk A/S | Phase 1 |
| Completed | Metabolic and Functional Impact of Various Breakfast Models NCT03240757 | Ospedale San Donato | N/A |
| Completed | Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance NCT00781937 | Novo Nordisk A/S | Phase 3 |
| Withdrawn | Examination of the Safety and Tolerability of NNC 0070-0002-0349 in Overweight/Obese Volunteers NCT00728455 | Novo Nordisk A/S | Phase 1 |
| Terminated | Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Fema NCT00665665 | Novo Nordisk A/S | Phase 1 |
| Completed | The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes NCT00422058 | Novo Nordisk A/S | Phase 2 |